Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

The Semaglutide cardiOvascular oUtcomes triaL (SOUL) recruited 9,650 people ... cerebrovascular disease, or chronic kidney disease. Participants were divided into a placebo group and a drug ...

Oral semaglutide reduced major ... type 2 diabetes over nearly 4 years. The trial involved 9650 patients with type 2 diabetes and cardiovascular or kidney disease, showing significant reductions ...

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

SOUL vs FLOW Speaking to the difference in outcomes between FLOW, a study where semaglutide cut both cardiovascular risk and the progression of kidney disease, and SOUL, where there was no effect on ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

CHICAGO — Semaglutide, a glucagon-like peptide ... and reductions in cardiovascular and kidney complications, he added. One trial showed a reduction in amputation related to diabetic foot ...

Semaglutide ... obesity, kidney disease, cardiovascular disease including atherosclerotic vascular disease and heart failure. In the trial called STRIDE, 792 people with type 2 diabetes and ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial ...